HCWB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HCW Biologics Inc (HCWB) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has shown significant price declines recently, lacks positive trading signals, and has weak financial performance. Despite some positive news catalysts, the overall sentiment and technical indicators do not support a strong long-term investment opportunity.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 52.755, showing no clear overbought or oversold condition. Moving averages are converging, suggesting indecision in price direction. The stock is trading below key support levels, with the next support at 0.509, indicating potential further downside.
HCW Biologics secured a $7 million upfront license fee from Beijing Trimmune, which includes cash and equity. Positive research results for CAR-T cell therapy HCW9206 were announced recently, leading to a temporary surge in pre-market trading.
The stock has experienced significant price declines: -18.60% in the regular market and -3.28% post-market. Financial performance is weak, with a 96.34% YoY revenue drop and negative EPS. Analysts predict further declines in the stock price over the next month.
In Q3 2025, revenue dropped by 96.34% YoY to $15,606. Net income improved slightly but remains negative at -$4,554,336. EPS dropped by 51.09% YoY to -2.02. Gross margin remained stagnant at 20%. Overall, the financials reflect poor growth trends and weak fundamentals.
No recent analyst ratings or price target changes are available. Hedge funds and insiders are neutral, showing no significant trading trends.
